Promomed Group has received an invention patent for Areplivir (favipiravir), a COVID-19 therapy in three different forms for parenteral administration: lyophilizate, concentrate, and powder. This was reported in the press service of the Group of Companies.
“Promomed was the first in the world to develop a complex unique technology for dissolving favipiravir, a substance that is nearly insoluble, and prepare stable injection forms based on it. The injectable form of the drug is not only 100% bioavailable, but also able to penetrate and spread in cells faster and stay in tissues in therapeutic concentration, and suitable for patients who cannot be administered tablets. This is especially important when taking measures to stop the critical development of the disease and achieve a rapid and maximum effect in hospitalized patients,” the report says.
The effectiveness compared with current standard-of-care (SoC) treatment in hospitalized patients and the safety of the use of Areplivir for parenteral administration were confirmed in a multicenter comparative clinical study led by Dmitry Pushkar, Academician of the Russian Academy of Sciences, Doctor of Sciences in Medicine, professor, member of Consortium of the Academic Community for the study of COVID-19, Promomed reports.
Areplivir, Russia’s first original domestic direct-acting antiviral for intravenous administration, received a registration certificate on November 12, 2021, and later was included in the updated, 14th version of the Ministry of Health’s temporary guidelines for the prevention, diagnosis and treatment of the novel coronavirus infection. On the same day, the first batch of the drug was shipped from Biokhimik plant (part of the Promomed group), according to the press service.
Earlier, it was reported that a new high-tech manufacturing facility opened at the Biokhimik plant of Promomed Group.
